PT656061E - Novas glicoformas do receptor do complemento 1 soluvel - Google Patents

Novas glicoformas do receptor do complemento 1 soluvel

Info

Publication number
PT656061E
PT656061E PT93918681T PT93918681T PT656061E PT 656061 E PT656061 E PT 656061E PT 93918681 T PT93918681 T PT 93918681T PT 93918681 T PT93918681 T PT 93918681T PT 656061 E PT656061 E PT 656061E
Authority
PT
Portugal
Prior art keywords
scr1
complement
soluvel
glyphorules
receptor
Prior art date
Application number
PT93918681T
Other languages
English (en)
Inventor
Henry C Marsh Jr
Richard A G Smith
Chang-Jing Grace Yeh
John Lifter
Anne Mary Freeman
Michael L Gosselin
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Publication of PT656061E publication Critical patent/PT656061E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT93918681T 1992-08-07 1993-08-06 Novas glicoformas do receptor do complemento 1 soluvel PT656061E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/927,099 US5456909A (en) 1992-08-07 1992-08-07 Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo

Publications (1)

Publication Number Publication Date
PT656061E true PT656061E (pt) 2004-03-31

Family

ID=25454172

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93918681T PT656061E (pt) 1992-08-07 1993-08-06 Novas glicoformas do receptor do complemento 1 soluvel

Country Status (15)

Country Link
US (3) US5456909A (pt)
EP (1) EP0656061B1 (pt)
JP (1) JP3662250B2 (pt)
CN (1) CN1089951A (pt)
AT (1) ATE253591T1 (pt)
CA (1) CA2141842C (pt)
DE (1) DE69333287T2 (pt)
DK (1) DK0656061T3 (pt)
ES (1) ES2210241T3 (pt)
IL (1) IL106558A (pt)
MX (1) MX9304800A (pt)
PT (1) PT656061E (pt)
TW (1) TW386878B (pt)
WO (1) WO1994003603A1 (pt)
ZA (1) ZA935728B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
WO1994026786A1 (en) * 1993-05-17 1994-11-24 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
DE69534701T2 (de) 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
BR9909220A (pt) * 1998-02-20 2000-11-21 Tanox Inc Inibidores de ativação de complemento
SE0004808D0 (sv) * 2000-12-20 2000-12-20 Apbiotech Ab Method for the purification of an enzyme
US20030096281A1 (en) * 2001-09-14 2003-05-22 Ganesh Venkataraman Methods of making glycomolecules with enhanced activities and uses thereof
US20040214228A9 (en) * 2001-09-14 2004-10-28 Ganesh Venkataraman Methods of evaluating glycomolecules for enhanced activities
EP1617888B1 (en) 2003-04-23 2019-06-12 Valeritas, Inc. Hydraulically actuated pump for long duration medicament administration
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
JP4507682B2 (ja) * 2004-04-26 2010-07-21 三菱化学株式会社 糖鎖分離方法、検体分析方法、液体クロマトグラフィー装置、並びに糖鎖分析方法及び糖鎖分析装置
ES2528362T3 (es) * 2004-05-14 2015-02-09 Alexion Pharmaceuticals, Inc. Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
EP3299027A1 (en) * 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
EP2253644B1 (en) 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions and methods for producing a composition
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
RS53864B1 (sr) 2006-03-02 2015-08-31 Alexion Pharmaceuticals, Inc. Produžavanje preživljavanja alografta inhibiranjem aktivnosti komplementa
KR101584468B1 (ko) 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
CN103239773B (zh) 2006-03-30 2015-08-26 瓦莱里塔斯公司 多筒式流体递送器械
CA2662480C (en) * 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
CN106188303A (zh) 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP5816170B2 (ja) * 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
US9295713B2 (en) 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
WO2012058479A2 (en) 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
CN103827134A (zh) * 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
SI3793586T1 (sl) * 2018-05-16 2024-07-31 Csl Limited Različice receptorja za topni komplement tipa 1 in njihova uporaba
EP3581203A1 (en) * 2018-06-11 2019-12-18 Laboratoire Français du Fractionnement et des Biotechnologies Antibodies with increased activity in the digestive tract
TW202128264A (zh) * 2019-09-25 2021-08-01 瑞士商赫孚孟拉羅股份公司 使用經預測之溶離緩衝鹽濃度的陽離子層析法
CA3259667A1 (en) * 2022-06-17 2023-12-21 CSL Innovation Pty Ltd Purification of a Soluble Complement Receptor and Variants thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo

Also Published As

Publication number Publication date
DE69333287D1 (de) 2003-12-11
DE69333287T2 (de) 2004-09-23
CA2141842C (en) 2008-07-29
US5456909A (en) 1995-10-10
US5858969A (en) 1999-01-12
US6057131A (en) 2000-05-02
IL106558A0 (en) 1993-12-08
ATE253591T1 (de) 2003-11-15
TW386878B (en) 2000-04-11
EP0656061B1 (en) 2003-11-05
CA2141842A1 (en) 1994-02-17
MX9304800A (es) 1994-05-31
DK0656061T3 (da) 2004-03-15
CN1089951A (zh) 1994-07-27
AU670453B2 (en) 1996-07-18
JPH08501773A (ja) 1996-02-27
WO1994003603A1 (en) 1994-02-17
IL106558A (en) 1998-10-30
AU4804193A (en) 1994-03-03
EP0656061A1 (en) 1995-06-07
JP3662250B2 (ja) 2005-06-22
ES2210241T3 (es) 2004-07-01
ZA935728B (en) 1994-03-03

Similar Documents

Publication Publication Date Title
PT656061E (pt) Novas glicoformas do receptor do complemento 1 soluvel
GR3007096T3 (pt)
EP0154344A3 (en) Antiviral pharmaceutical preparations and methods for their use
MX9702932A (es) L-ribofuranosilnucleosidos.
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
KR100206481B1 (en) Galenic form for ocular administration and process for the preparation of same
HUT59000A (en) Process for producing pharmaceutical preparations containing 4-phenyl-1,2,3,4-tetrahydro-1-naphtalinamine-derivatives
ZA874635B (en) Novel anti-inflammatory agents,pharmaceutical compositions and methods for reducing inflammation
ES8607732A1 (es) Procedimiento para producir un preparado implantable de un peptido regulador, uno de sus analogos o una de sus sales fisiologicamente compatibles.
MY109143A (en) Sulfonamido-and sulfonamidocarbonylpyridine 2-carboxamides and their pyridine-n-oxides, process for their preparation and their use as pharmaceuticals
GB2151244B (en) Insolubilized biocompatible hyaluronic acid preparations
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
MY109990A (en) Microfluidised particles of atovaquone and pharmaceutical preparation thereof
MY106528A (en) Method of treating impotence.
HUT63063A (en) Process for producing antibodies against cd44 cell surface glycoprotein and immunosuppressant pharmaceutical compositions comprising same
CA2198706A1 (en) Methods for the treatment of inflammatory joint disease
ITMI922331A0 (it) Uso di paratormone suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto protermine ed in generale per il trattamento della gestazione
GR3006815T3 (pt)
IT9067434A0 (it) Procedimento per migliorare l'efficacia terapeutica di corticosteroidi liposolubili e composizione per l'attuazione di tale procedimento
CA2090011A1 (en) Anti-inflammatory factor, method of isolation, and use
HU9202075D0 (en) Bcrf1 proteins of gamma-interferon inhibiting effect
EP0336368A3 (en) N2-(1-carboxy-3-phenylpropyl)-l-lysine derivative and process of producing lysinopril using the compound
MX9702926A (es) L-eritrosilnucleosidos.
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
EP0282343A3 (en) Method to stimulate the immune response to specific antigens